2028, Chemotherapy and Labelling

High risk, high reward – the future of CAR-T therapy in CLL

Pharmaceutical Technology

OCTOBER 5, 2022

According to GlobalData’s analyst consensus forecast, Yescarta is expected to reach peak sales of $1.8bn in 2028, and Kymriah is expected to reach sales of $686m in the same year. Autologous CAR-T agents are now becoming the standard of care for patients in the third line and later settings, providing lucrative returns for these agents.

Chemotherapy

Chemotherapy Labelling

MSD’s Keytruda use in adenocarcinoma could be limited based on biomarker

Pharmaceutical Technology

JUNE 16, 2023

Merck ( MSD ) has announced updated results with Keytruda (pembrolizumab) in the Phase III Keynote-811 trial, which opens up the possibility of changing the checkpoint inhibitor’s label in HER2-positive gastric or GEJ adenocarcinoma so it’s based on the tumour’s PD-L1 biomarker status. It showed promising event-free survival (EFS) of 62.4%

Chemotherapy

Chemotherapy Labelling Communication

Pharmacist Digest

High risk, high reward – the future of CAR-T therapy in CLL

MSD’s Keytruda use in adenocarcinoma could be limited based on biomarker

Webinars

Stay Connected